For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... providing a background level of blood glucose control ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...

While not super cheap today, at 26 times trailing earnings and with growth prospects perking up, it may be time to take another look at Novo Nordisk stock. Rich Smith has no position in any of the ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 and December 19, 2024, both dates inclusive (the ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s dominance over the weight-loss industry. The Danish pharma giant ...

Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling ...

Novo Nordisk shares have dropped significantly in ... The chart below says "No." That's likely because the company keeps growing its earnings, and this is set to continue. So, is now really ...

Here's why the stock may be a no-brainer buy right now. Last week, Novo Nordisk released its year-end results, including how it performed over the last three months of 2024. Net sales for the ...